Urogen Pharma Ltd

詳細情報 Urogen Pharma Ltd 企業名

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

企業情報

企業コードURGN

会社名Urogen Pharma Ltd

上場日May 04, 2017

最高経営責任者「CEO」Ms. Elizabeth A. (Liz) Barrett

従業員数235

証券種類Ordinary Share

決算期末May 04

本社所在地9 Ha'ta'asiya St

都市RA'ANANA

証券取引所NASDAQ Global Market Consolidated

国Israel

郵便番号4365007

電話番号97297707601

ウェブサイトhttps://www.urogen.com/

企業コードURGN

上場日May 04, 2017

最高経営責任者「CEO」Ms. Elizabeth A. (Liz) Barrett

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+4.37%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

--

Mr. James A. Robinson, Jr.

Independent Director

--

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

--

Ms. Cynthia M. Butitta

Independent Director

--

Dr. Leana S. Wen, M.D.

Independent Director

--

Mr. Vincent Perrone

Investor Relations

--

Mr. Daniel G. Wildman

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+4.37%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

--

Mr. James A. Robinson, Jr.

Independent Director

--

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

事業別USD

会社名

収益

比率

Jelmyto

20.25M

0.00%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

Jelmyto

20.25M

0.00%

株主

更新時刻: Tue, Aug 19

株主統計

種類

株主統計

比率

RTW Investments L.P.

9.82%

TD Securities, Inc.

6.90%

Paradigm BioCapital Advisors LP

5.04%

Jefferies LLC

4.75%

Soleus Capital Management, L.P.

4.72%

他の

68.76%

株主統計

比率

RTW Investments L.P.

9.82%

TD Securities, Inc.

6.90%

Paradigm BioCapital Advisors LP

5.04%

Jefferies LLC

4.75%

Soleus Capital Management, L.P.

4.72%

他の

68.76%

種類

株主統計

比率

Hedge Fund

29.41%

Research Firm

21.31%

Investment Advisor/Hedge Fund

20.23%

Investment Advisor

17.86%

Corporation

4.77%

Insurance Company

4.19%

Venture Capital

3.21%

Private Equity

2.11%

Individual Investor

2.09%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

285

53.00M

114.72%

+5.27M

2025Q1

290

49.25M

108.64%

+1.67M

2024Q4

280

43.94M

103.24%

-1.94M

2024Q3

262

44.13M

104.63%

-2.19M

2024Q2

247

46.02M

111.40%

+11.07M

2024Q1

255

34.96M

99.86%

+5.57M

2023Q4

237

29.16M

94.80%

+4.33M

2023Q3

238

25.93M

86.41%

+2.69M

2023Q2

222

19.52M

83.40%

-392.05K

2023Q1

221

19.00M

81.20%

-1.17M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

RTW Investments L.P.

3.83M

8.32%

--

Mar 31, 2025

TD Securities, Inc.

2.65M

5.75%

+903.36K

+51.65%

Jun 09, 2025

Jefferies LLC

815.00K

1.77%

-150.93K

-15.63%

Mar 31, 2025

Soleus Capital Management, L.P.

2.33M

5.04%

+2.33M

--

Jun 13, 2025

BlackRock Institutional Trust Company, N.A.

2.14M

4.65%

-50.01K

-2.28%

Mar 31, 2025

SilverArc Capital Management, LLC

1.38M

3%

+260.69K

+23.27%

Mar 31, 2025

Pontifax Venture Capital

1.49M

3.22%

-1.00

-0.00%

Mar 14, 2024

Arkin Communication, Ltd.

1.37M

2.97%

--

Feb 22, 2024

詳細を見る

18.870USD

Urogen Pharma Ltd

18.870

概要

企業名

金融

分析